Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1997 1
2001 1
2004 2
2008 2
2009 2
2010 1
2011 4
2012 2
2014 3
2015 4
2016 1
2017 4
2018 3
2019 4
2020 7
2021 2
2022 1
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Epithelioid Mesothelioma"
Page 1
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
Fennell DA, Ewings S, Ottensmeier C, Califano R, Hanna GG, Hill K, Danson S, Steele N, Nye M, Johnson L, Lord J, Middleton C, Szlosarek P, Chan S, Gaba A, Darlison L, Wells-Jordan P, Richards C, Poile C, Lester JF, Griffiths G; CONFIRM trial investigators. Fennell DA, et al. Lancet Oncol. 2021 Nov;22(11):1530-1540. doi: 10.1016/S1470-2045(21)00471-X. Epub 2021 Oct 14. Lancet Oncol. 2021. PMID: 34656227 Free PMC article. Clinical Trial.
BACKGROUND: No phase 3 trial has yet shown improved survival for patients with pleural or peritoneal malignant mesothelioma who have progressed following platinum-based chemotherapy. ...INTERPRETATION: Nivolumab represents a treatment that might be beneficial to pat …
BACKGROUND: No phase 3 trial has yet shown improved survival for patients with pleural or peritoneal malignant mesothelioma wh …
Characterizing the distribution of alterations in mesothelioma and their correlation to morphology.
Chen-Yost HI, Tjota MY, Gao G, Mitchell O, Kindler H, Segal J, Husain AN, Mueller J, Schulte JJ. Chen-Yost HI, et al. Am J Clin Pathol. 2023 Sep 1;160(3):238-246. doi: 10.1093/ajcp/aqad041. Am J Clin Pathol. 2023. PMID: 37141416 Review.
Several recurrent alterations have been observed in pleural and peritoneal -mesotheliomas, including in BAP1, NF2, and CDKN2A. ...There were 109 epithelioid mesotheliomas, 18 biphasic mesotheliomas, and 4 sarcomatoid mesotheliomas. ...
Several recurrent alterations have been observed in pleural and peritoneal -mesotheliomas, including in BAP1, NF2, and CDKN2A. …
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto N. Geoerger B, et al. Lancet Oncol. 2020 Jan;21(1):121-133. doi: 10.1016/S1470-2045(19)30671-0. Epub 2019 Dec 4. Lancet Oncol. 2020. PMID: 31812554 Clinical Trial.
Of 136 patients with solid tumours and other lymphomas, eight had partial responses (two patients each with adrenocortical carcinoma and mesothelioma, and one patient each with malignant ganglioglioma, epithelioid sarcoma, lymphoepithelial carcinoma, and m …
Of 136 patients with solid tumours and other lymphomas, eight had partial responses (two patients each with adrenocortical carcinoma and …
Pathohistological diagnosis and differential diagnosis.
Tischoff I, Neid M, Neumann V, Tannapfel A. Tischoff I, et al. Recent Results Cancer Res. 2011;189:57-78. doi: 10.1007/978-3-642-10862-4_5. Recent Results Cancer Res. 2011. PMID: 21479896 Review.
Epithelioid type is the most frequent one, but biphasic malignant mesothelioma occurs in 30%. ...Histological type is an important prognostic marker. Longest survival is seen in patients with epithelioid malignant mesothelioma. ...
Epithelioid type is the most frequent one, but biphasic malignant mesothelioma occurs in 30%. ...Histological type is a …
Multicystic and diffuse malignant peritoneal mesothelioma in children.
Vermersch S, Arnaud A, Orbach D, Andre N, Berger C, Kepenekian V, Brigand C, Fresneau B, Poli-Merol ML, Habougit C, Varlet F, Scalabre A. Vermersch S, et al. Pediatr Blood Cancer. 2020 Jun;67(6):e28286. doi: 10.1002/pbc.28286. Epub 2020 Apr 11. Pediatr Blood Cancer. 2020. PMID: 32277799
BACKGROUND: Malignant and multicystic peritoneal mesotheliomas are extremely rare tumors in children, developing from mesothelial cells. ...The most frequent presenting symptoms were abdominal pain, ascitis, and alteration in the general condition. Eight patients ha …
BACKGROUND: Malignant and multicystic peritoneal mesotheliomas are extremely rare tumors in children, developing from mesothel …
Adjuvant dendritic cell-based immunotherapy after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with malignant peritoneal mesothelioma: a phase II clinical trial.
Dietz MV, Quintelier KLA, van Kooten JP, de Boer NL, Vink M, Brandt-Kerkhof ARM, Verhoef C, Saeys Y, Aerts JGJV, Willemsen M, Van Gassen S, Madsen EVE. Dietz MV, et al. J Immunother Cancer. 2023 Aug;11(8):e007070. doi: 10.1136/jitc-2023-007070. J Immunother Cancer. 2023. PMID: 37536940 Free PMC article. Clinical Trial.
BACKGROUND: Malignant peritoneal mesothelioma (MPM) is an aggressive malignancy with a poor prognosis. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) improves survival outcomes, but recurrence rates remain high. Dendr …
BACKGROUND: Malignant peritoneal mesothelioma (MPM) is an aggressive malignancy with a poor prognosis. Cytoreductive su …
The role of 18F-FDG-PET/ceCT in peritoneal mesothelioma.
Dubreuil J, Giammarile F, Rousset P, Rubello D, Bakrin N, Passot G, Isaac S, Glehen O, Skanjeti A. Dubreuil J, et al. Nucl Med Commun. 2017 Apr;38(4):312-318. doi: 10.1097/MNM.0000000000000649. Nucl Med Commun. 2017. PMID: 28244976
PURPOSE: The aim of this study was to assess glucose metabolism of multicystic peritoneal mesothelioma and epithelioid peritoneal mesothelioma by fluorine-18 fluorodeoxyglucose (F-FDG)-PET/contrast-enhanced computed tomography (ceCT) and to assess its prog …
PURPOSE: The aim of this study was to assess glucose metabolism of multicystic peritoneal mesothelioma and epithelioid periton …
Laryngeal sarcomas: A case series of 5 cases.
AbdullGaffar B, Keloth T. AbdullGaffar B, et al. Ann Diagn Pathol. 2018 Dec;37:35-41. doi: 10.1016/j.anndiagpath.2018.09.007. Epub 2018 Sep 14. Ann Diagn Pathol. 2018. PMID: 30241033
Sarcomas can have heterogeneous morphologic features of spindle, small round, epithelioid, pleomorphic and giant cells. Laryngeal sarcomas may mimic carcinomas, lymphomas, small cell carcinoma, mesothelioma and melanoma. ...Correct diagnosis, classification and grad …
Sarcomas can have heterogeneous morphologic features of spindle, small round, epithelioid, pleomorphic and giant cells. Laryngeal sar …
Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma: Canadian practices and outcomes.
Deban M, Taqi K, Knapp GC, Soucisse M, Curry M, Sidéris L, Dubé P, Khaldi MA, Jedrzejko N, Porter G, Giacomantonio C, Hamilton T, MacNeill A, Mack L, Bouchard-Fortier A. Deban M, et al. J Surg Oncol. 2023 Sep;128(4):595-603. doi: 10.1002/jso.27301. Epub 2023 May 30. J Surg Oncol. 2023. PMID: 37249154
INTRODUCTION: Peritoneal mesothelioma (PM) is a rare malignancy originating from the peritoneal lining. ...Mean age was 52 years (17-75) and 37.5% were male. Epithelioid (70.1%) and multicystic (13%) mesothelioma were the most common subtypes. ...
INTRODUCTION: Peritoneal mesothelioma (PM) is a rare malignancy originating from the peritoneal lining. ...Mean age was 52 years (17- …
Mesothelin expression remodeled the immune-matrix tumor microenvironment predicting the risk of death in patients with malignant pleural mesothelioma.
Qualiotto AN, Baldavira CM, Balancin M, Ab'Saber A, Takagaki T, Capelozzi VL. Qualiotto AN, et al. Front Immunol. 2023 Oct 12;14:1268927. doi: 10.3389/fimmu.2023.1268927. eCollection 2023. Front Immunol. 2023. PMID: 37901248 Free PMC article.
BACKGROUND: The combination of immunobiological agents with immune checkpoint proteins is a promising treatment for malignant pleural mesothelioma (MPM). Mesothelin and anti-PD-L1 antibody-drug conjugates specifically target malignant neoplastic cells, inhibi …
BACKGROUND: The combination of immunobiological agents with immune checkpoint proteins is a promising treatment for malignant pleural …
43 results